If You Invested $10K In Abbott Laboratories Stock 10 Years Ago, How Much Would You Have Now?

Abbott Laboratories ABT discovers, develops, manufactures, and sells healthcare products worldwide.

Get Started

Earn 7.2% — No Matter What the Fed Does

Markets expect rate cuts — but your earnings don’t have to suffer. Lock in 7.2% until 2028 from ten individual bonds.

Get Started

If You Bought Abbott Laboratories Stock 10 Years Ago

The company's stock traded at approximately $49.14 per share 10 years ago. If you had invested $10,000, you could have bought roughly 204 shares. Currently, shares trade at $134.92, meaning your investment's value could have grown to $27,456 from stock price appreciation alone. However, Abbott Laboratories also paid dividends during these 10 years. 

Don't Miss:

• Hasbro, MGM, and Skechers trust this AI marketing firm — Invest at $0.60/share before it's too late.
• Deloitte's fastest-growing software company partners with Amazon, Walmart & Target – Last Chance to get 4,000 of its pre-IPO shares for just $0.30/share!

Abbott Laboratories' dividend yield is currently 1.74%. Over the last 10 years, it has paid about $16 in dividends per share, which means you could have made $3,256 from dividends alone. 

Summing up $27,456 and $3,256, we end up with the final value of your investment, which is $30,712. This is how much you could have made if you had invested $10,000 in Abbott Laboratories stock 10 years ago. This means a total return of 207.12%. However, this figure is less than the S&P 500 total return for the same period, which was 234.20%.

Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — you can become an investor for $0.80 per share today.

What Could The Next 10 Years Bring? 

Abbott Laboratories has a consensus rating of "Buy" and a price target of $137.12 based on the ratings of 27 analysts. The price target implies a nearly 2% potential upside from the current stock price.

On April 16, the company announced its Q1 2025 earnings, posting revenues of $10.36 billion, compared to the consensus of $10.40 billion, as reported by Benzinga. The U.S. MedTech giant reported adjusted EPS of $1.09, beating the consensus of $1.07.

"Once again, Abbott's diversified business model delivered top-tier sales and EPS growth," said CEO Robert Ford. "It is this diversification and execution that allows Abbott to navigate through periods of uncertainty and continually deliver sustainable growth."

See Also: Nancy Pelosi Invested $5 Million In An AI Company Last Year — Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.

Abbott reaffirmed its full-year 2025 adjusted EPS guidance in the range of $5.05 to $5.25, compared to the consensus estimate of $5.15. Q2 2025 adjusted EPS is expected to be between $1.23 and $1.27, compared to the consensus of $1.25.

Given the expected downside potential, growth-focused investors may not find Abbott Laboratories stock attractive. Conversely, the stock can be a good option for income-focused investors, who can benefit from the company's solid dividend yield of 1.74% and consistent hikes. Abbott Laboratories has raised its dividend consecutively for the last 51 years.

Check out this article by Benzinga for three more stocks offering high dividend yields. 

Read Next:

• Invest Where It Hurts — And Help Millions Heal: Invest in Cytonics and help disrupt a $390B Big Pharma stronghold.
• ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can invest today for just $0.30/share with a $1000 minimum.

Image: Shutterstock